ClinicalTrials.gg
CompletedNCT06715683Updated Apr 4, 2025

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

A Phase 1 interventional study of BMS-986278 Batched method, Dose A and BMS-986278 Batched method, Dose B in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a trial to evaluate the comparative bioavailability of BMS-986278 to-be-marketed formulation compared to the phase 3 clinical trial formulation in healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
  • Comparative Bioavailability
  • BMS-986278
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female individuals not of (INOCBP) and males, healthy as determined by medical history, physical examination, vital signs, 12-lead (ECG), and clinical laboratory assessment results as determined by the investigator.
  • (BMI) 18.0 to 32.0 kg/m2, inclusive.
  • Body weight ≥ 50 kg for males and ≥ 45 kg for females.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness as determined by the investigator.
  • Current or recent (within 3 months of study intervention administration) gastrointestinal (GI) disease or other procedures (eg, bariatric procedures) that could affect drug absorption, distribution, metabolism, and excretion. Note: uncomplicated appendectomy and hernia repair are acceptable).
  • Any major surgery within 4 weeks of study intervention administration on Day 1, including GI surgery (eg, cholecystectomy and any other GI surgery or perforation that could impact upon the absorption of study intervention [uncomplicated appendectomy and hernia repair are acceptable]).
  • History of known risk of bleeding.
  • Inability to tolerate oral medication.
  • Individuals (only females) who are of .
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part 1, Sequence 1

    Drug: BMS-986278 Batched method, Dose A · Drug: BMS-986278 Batched method, Dose B

  • Experimental
    Part 1, Sequence 2

    Drug: BMS-986278 Batched method, Dose A · Drug: BMS-986278 Batched method, Dose B

  • Experimental
    Part 2, Sequence 1

    Drug: BMS-986278 Batched method, Dose A · Drug: BMS-986278 Continuous method

  • Experimental
    Part 2, Sequence 2

    Drug: BMS-986278 Batched method, Dose A · Drug: BMS-986278 Continuous method

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to Day 24

  2. Area Under the Concentration-time From Time Zero to Time Last Qualifiable Concentration (AUC(0-T))

    Time frame: Up to Day 24

  3. Area Under the Concentration-time From Time Zero Extrapolated to Infinite Time (AUC(INF))

    Time frame: Up to Day 24

Secondary outcomes

  1. Time of Maximum Observed Plasma Concentration (Tmax)

    Time frame: Up to Day 24

  2. Terminal Phase Half-life (T-HALF)

    Time frame: Up to Day 24

  3. Apparent Total Body Clearance (CLT/F)

    Time frame: Up to Day 24

  4. Apparent Volume of Distribution (Vz/F)

    Time frame: Up to Day 24

  5. Number of Participants With Adverse Events (AEs)

    Time frame: Up to 28 Days Post-discontinuation of Study Intervention

  6. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Up to Day 25

  7. Number of Participants With Vital Sign Abnormalities

    Time frame: Up to Day 25

  8. Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities

    Time frame: Up to Day 25

07

Study locations

1 site
  • Anaheim Clinical Trials (ACT)
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Mar 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2024
First posted
Dec 4, 2024
StartActual
Dec 12, 2024
Primary completionActual
Mar 16, 2025
CompletionActual
Mar 16, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715683
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Dec 12, 2024
Primary completion
Mar 16, 2025
Completion
Mar 16, 2025
Last update
Apr 4, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion